FDA approves Tzield teplizumab as first disease-modifying therapy for newly diagnosed type 1 diabetes in children aged 8 to 17
Children 8 to 17 newly diagnosed with type 1 diabetes can now get a drug that protects their own remaining insulin-producing cells, not just replaces the hormone. The FDA approved Tzield (teplizumab) from Sanofi $SNY on June 12 as the first disease-modifying therapy at this stage
For children aged 8 to 17 who have just been diagnosed with type 1 diabetes, treatment has always meant one thing: replacing the insulin their body can no longer make. That changed on June 12, when the US Food and Drug Administration granted accelerated approval to Tzield (teplizumab), made by Sanofi $SNY, as the first disease-modifying therapy for patients recently diagnosed with Stage 3 type 1 diabetes. Instead of substituting for lost insulin, the drug targets the immune attack itself, aiming to slow the destruction of the insulin-producing beta cells that still remain at diagnosis. The approval rests on the PROTECT phase 3 trial, which enrolled children diagnosed within the previous six weeks who still had measurable beta-cell output. In that study, teplizumab preserved beta-cell function compared with placebo, measured by stimulated C-peptide levels at 78 weeks. The shift matters because the weeks right after diagnosis are when the most insulin-making capacity survives. For the first time, that window becomes something a treatment can act on rather than simply manage. The FDA cleared the drug under its accelerated pathway using C-peptide as a surrogate marker, and a postapproval study is ongoing to confirm long-term clinical benefit.